B
Blueprint Medicines
Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases
At a glance
- Status
- Listed
- Listing
- IPO 2015
Open roles
Blueprint Medicines in the Cambridge ecosystem
The Blueprint Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Series B and later4 investors entered at this stage
- NINextech Invest
- PSPFM Health Sciences
RA Capital Management
Casdin Capital
Source: Dealroom Talent Intelligence.
Alumni founders
Former Blueprint Medicines employees who went on to found companies, sorted by Dealroom signal score.
STSolve TherapeuticsEst. 2021
Dave JohnsonUnited States
RPRecludix PharmaEst. 2019
NTNested TherapeuticsEst. 2021
Klaus HoeflichUnited States
FMFrontier MedicinesEst. 2018
Chris VarmaUnited States
CTCelsius TherapeuticsEst. 2018
Christoph LengauerUnited StatesPatents
80 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Blueprint Medicines on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Sanofi acquires Blueprint (July 2025)
Ringg lands $10M from Peak XV to expand voice AI beyond calls


